Minerva Neurosciences (NERV)
(Delayed Data from NSDQ)
$2.63 USD
+0.04 (1.54%)
Updated Aug 23, 2024 03:06 PM ET
After-Market: $2.64 +0.01 (0.38%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
Balance Sheet
Fiscal Year End for Minerva Neurosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 41 | 36 | 61 | 25 | 46 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 4 | 1 | 2 | 1 |
Total Current Assets | 42 | 40 | 62 | 27 | 47 |
Net Property & Equipment | 0 | 0 | 0 | 15 | 15 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 15 | 15 | 15 | 15 | 15 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 57 | 55 | 77 | 58 | 78 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 1 | 2 | 1 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 2 | 0 | 1 | 2 | 4 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 3 | 1 | 3 | 3 | 7 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 2 | 43 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 82 | 74 | 66 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 85 | 75 | 69 | 5 | 50 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 368 | 347 | 343 | 337 | 315 |
Retained Earnings | -397 | -367 | -335 | -285 | -287 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -28 | -20 | 8 | 53 | 28 |
Total Liabilities & Shareholder's Equity | 57 | 55 | 77 | 58 | 78 |
Total Common Equity | -28 | -20 | 8 | 53 | 28 |
Shares Outstanding | 6.90 | 5.30 | 5.30 | 5.30 | 4.80 |
Book Value Per Share | -4.12 | -3.78 | 1.51 | 9.94 | 5.79 |
Fiscal Year End for Minerva Neurosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 31 | 35 | 41 | 47 | 52 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 0 | 1 | 1 | 1 | 0 |
Total Current Assets | 31 | 36 | 42 | 48 | 52 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 15 | 15 | 15 | 15 | 15 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 46 | 51 | 57 | 63 | 67 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 1 | 2 | 1 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 3 | 1 | 2 | 2 | 2 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 4 | 3 | 3 | 3 | 2 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 87 | 82 | 80 | 78 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 91 | 87 | 85 | 83 | 80 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 369 | 369 | 368 | 368 | 367 |
Retained Earnings | -414 | -405 | -397 | -388 | -380 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -44 | -37 | -28 | -20 | -13 |
Total Liabilities & Shareholder's Equity | 46 | 51 | 57 | 63 | 67 |
Total Common Equity | -44 | -37 | -28 | -20 | -13 |
Shares Outstanding | 6.90 | 6.90 | 6.90 | 6.90 | 6.90 |
Book Value Per Share | -6.45 | -5.30 | -4.12 | -2.91 | -1.81 |